Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Target identification and validation in systemic autoimmunity.

Stanford L Peng1

  • 1Department of Internal Medicine/Rheumatology, Washington University School of Medicine St. Louis, MO 63110, USA. speng@wustl.edu

Immunologic Research
|August 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.

Kidney international reports·2026
Same author

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.

Frontiers in immunology·2025
Same author

A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.

Clinical and translational science·2024
Same author

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.

Journal for immunotherapy of cancer·2024
Same author

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Journal for immunotherapy of cancer·2024
Same author

Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
Same journal

Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil.

Immunologic research·2026
Same journal

Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway.

Immunologic research·2026
Same journal

Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.

Immunologic research·2026
See all related articles

New research highlights novel genetic targets for autoimmune diseases like lupus. Understanding genes regulating T- and B-cell function offers hope for developing more effective autoimmune therapies.

Area of Science:

  • Immunology
  • Genetics
  • Autoimmune Diseases

Background:

  • Systemic autoimmune diseases, such as systemic lupus erythematosus, involve hyperactive T- and B-lymphocytes producing autoantibodies that damage organs.
  • Current understanding of molecules and cytokines (e.g., CD154, interferons) is insufficient to fully explain disease pathophysiology or identify effective therapeutic targets.

Purpose of the Study:

  • To identify novel pathogenic targets in autoimmune diseases through genome-based approaches.
  • To explore genes regulating lymphocyte differentiation and T-cell-B-cell collaboration as potential therapeutic avenues.

Main Methods:

  • Genome-based approaches to identify novel genetic targets in autoimmunity.
  • Analysis of genes regulating T- and B-cell effector differentiation.

Related Experiment Videos

  • Investigation of genes controlling T-cell-B-cell collaboration.

    • Main Results:

    • Genome-based studies have identified novel pathogenic targets in autoimmunity.
    • Key targets include genes that negatively regulate T- and/or B-cell differentiation.
    • Genes specifically regulating T-cell-B-cell collaboration are also implicated.

    Conclusions:

    • Novel therapeutic targets for autoimmune conditions are emerging from genetic research.
    • Focusing on genes regulating lymphocyte function and collaboration may lead to specific treatments.
    • Continued investigation holds promise for developing new therapies for human autoimmune diseases.